skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
PI3K-beta Inhibitor GSK2636771 (Code C106261)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: PI3K-beta Inhibitor GSK2636771

Definition: An orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor GSK2636771 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K beta-expressing and/or PTEN-driven tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells.

Display Name: PI3K-beta Inhibitor GSK2636771

Label: PI3K-beta Inhibitor GSK2636771

NCI Thesaurus Code: C106261 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL433894  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
GSK2636771
PI3K-beta Inhibitor GSK2636771

External Source Codes: 
PDQ Closed Trial Search ID 715683
PDQ Open Trial Search ID 715683 (check for NCI PDQ open clinical trial info)
NCI META CUI CL433894

Other Properties:
     Name Value (qualifiers indented underneath)
code C106261
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C106261

Mainbox Bottom